Bloomberg BNA, September 8, 2016. High-risk medical devices are sometimes approved using low-quality clinical data and this increases Medicare costs, a member of a Medicare congressional advisory panel said Sept. 8. “I agree completely” says Dr. Diana Zuckerman of NCHR
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
The ‘Grassroots Campaign’ for ‘Female Viagra’ Was Actually Funded by Its Manufacturer
New York Magazine’s The Cut, September 8, 2016. The “It” drug was Addyi, Sprout Pharmaceutical’s answer to low libido in women, approved by the FDA last August and now in the news for its low sales and for turning out to be a bit of a dud, effectiveness-wise.
Read More »I-Team: Company Behind EpiPen Fought to Keep Cheaper Generic Off Market
NBC4 New York, August 31, 2016. The CEO of Mylan Pharmaceuticals announced the launch of its own cheaper version of the EpiPen but previously fought to keep prices high by limiting options.
Read More »Part D Pricing Trends
POLITICO Prescription Pulse, August 22, 2016. Medtronic is facing allegations that it promoted a device for uses not approved by FDA. “If the device had been tested in a clinical trial it would have been clear that it was designed to fit a part of the spine the company wasn’t seeking approval for,” Diana Zuckerman of the National Center for Health Research explained to STAT.
Read More »PDUFA Again: Still Trying to Get It Right
MedPage Today, August 20, 2016: The Pharmaceutical Industry and some patient groups praised the latest drug user fee plan (PDUFA), but consumer advocates warned that drug safety is compromised when the focus is on faster approvals.
Read More »